Tag: Bioniz Therapeutics
Equillium acquires Bioniz Therapeutics to expand immunomodulatory drug pipeline
Equillium, a Nasdaq-listed biotech company, has acquired Bioniz Therapeutics in a deal worth up to around $329 million, in a move to considerably expand its ... Read More
Bioniz Therapeutics gets EC orphan drug status for BNZ-1 for CTCL
Bioniz Therapeutics has secured orphan drug designation for BNZ-1 from the European Commission (EC) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare type ... Read More
Bioniz Therapeutics announces positive data from BNZ-1 phase 1/2 trial in rCTCL
Bioniz Therapeutics has announced positive data from a phase 1/2 clinical trial of BNZ-1 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (rCTCL). ... Read More